On November 17th, Novo Nordisk's injection of semaglutide for long-term weight management was officially launched in China. Regarding the listing of Novo Nordisk, in terms of listing channels, Novo Nordisk told the Beijing News Shell Finance reporter on the same day that the company will increase the accessibility of the drug based on the principle of being responsible to patients. After listing, according to the distribution of obese patients, the drug will be sold through multiple channels including public hospitals, private hospitals, and pharmacies.
In addition, Novo Nordisk also stated that currently, the company has not sold Novo Nordisk through any online platforms (including e-commerce, social media, etc.), nor has it authorized or commissioned any third party to sell Novo Nordisk on online platforms.
According to information released by the National Medical Products Administration (NMPA), the marketing application for Novo Nordisk was approved in June of this year.
Before NovoPlus was approved for listing, because of the weight loss effect of Smeglutide, NovoPlus's Smeglutide injection, which is used for the treatment of adult type 2 diabetes, has been used in China for over indications. Novo Nordisk suggests that Novo Plus, which is used for long-term weight management of adults, and Novotel, which is used for the treatment of adult type 2 diabetes, are prescription drugs. These two drugs are used to treat two different diseases and cannot be replaced by each other.